Improving blood vessel integration in organ transplants for diabetes treatment
Angiogenic hydrogel composites for microvascular integration of organoid grafts
This study is looking at new ways to help blood vessels grow in organ transplants for people with type I diabetes, using special gels that could make it easier for transplanted cells to survive and help control insulin and sugar levels in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10813726 on NIH RePORTER |
What this research studies
This research focuses on enhancing the integration of blood vessels in organ grafts, specifically for patients with type I diabetes. By using specialized hydrogels that promote the growth of blood vessels, the study aims to improve the survival of transplanted cells and their ability to regulate insulin and glucose levels in the body. The approach involves engineering biomaterials that mimic the natural cues necessary for blood vessel formation, which is crucial for the success of cell replacement therapies. Patients may benefit from advancements in organ transplantation techniques that could lead to better management of diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type I diabetes who may benefit from cell replacement therapies.
Not a fit: Patients with type II diabetes or those not requiring organ transplants may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved outcomes for diabetes patients requiring organ transplants by enhancing graft survival and function.
How similar studies have performed: Previous research has shown promise in using hydrogels for vascular integration, indicating that this approach may lead to significant advancements in the field.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Baker, Brendon M — University of Michigan at Ann Arbor
- Study coordinator: Baker, Brendon M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.